Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial...

Published on 17 Dec 2024 on GuruFocus.com · via Yahoo Finance

Conducted across the U.S., Europe, and Israel, the trial met its primary endpoints, showing 47.8%...

Read the rest of the article

Start tracking your investments with Statfolio

Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than avera...

Zacks · via Yahoo Finance 18 Dec 2024

Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced...

Invezz 18 Dec 2024

Teva and Sanofi reported successful results in their phase 2 study of an IBD treatment. Both stoc...

Investing.com 18 Dec 2024

Teva stock soared 26.4% to 20.88 after briefly hitting its highest point since December 2018. San...

Investor's Business Daily 17 Dec 2024

Teva and Sanofi said they plan to launch a Phase 3 trial for duvakitug pending regulatory...

Investopedia · via Yahoo Finance 17 Dec 2024

Conducted across the U.S., Europe, and Israel, the trial met its primary endpoints, showing 47.8%...

GuruFocus.com · via Yahoo Finance 17 Dec 2024

On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b...

Benzinga · via Yahoo Finance 17 Dec 2024

Teva and its partner Sanofi say 47.8% of patients with ulcerative colitis who received a high dos...

Barrons.com 17 Dec 2024

It also anticipates a portion of the costs of both these years to be reimbursed by Sanofi. How Ha...

Zacks · via Yahoo Finance 12 Dec 2024

Comings and goings at local biotech companies continue into the final days of the year, and the...

The Business Journals 12 Dec 2024